# To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina

> **NCT02623569** · PHASE2 · UNKNOWN · sponsor: **Xintong Pharmacy Company** · enrollment: 336 (estimated)

## Conditions studied

- Angina Pectoris

## Interventions

- **DRUG:** Ivabradine
- **DRUG:** Atenolol

## Key facts

- **NCT ID:** NCT02623569
- **Lead sponsor:** Xintong Pharmacy Company
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623569, "To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02623569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*